Spyre Therapeutics, Inc. SYRE
96.59 USD -2.45 (-2.47%)
At closeNov 5, 2026, 4:00 PM EST
96.59 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
93.83 Day range 98.75
21.15 52-week range 110.18
- YTD
- +194.84%
- 1 year
- +322.71%
News
benzinga.com Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135 Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $130 to $135.
benzinga.com Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $120 Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $123 to $120.
benzinga.com Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, while Amdocs plunged 39% after missing Q4 estimates and issuing weak FY27 guidance; several other stocks also fell premarket.
globenewswire.com Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), completing proof-of-concept for all three monotherapies in inflammatory bowel disease…
benzinga.com BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
globenewswire.com Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the…
benzinga.com UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120 UBS analyst Alice Nettleton initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $120.
seekingalpha.com Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential Spyre Therapeutics maintains a 'Strong Buy' rating, driven by promising IBD pipeline progress and robust cash reserves. SYRE's three monotherapy candidates—SPY001, SPY002, SPY003—show potential…
benzinga.com Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 Earnings U.S. stocks rose Tuesday: Dow +350 points, S&P 500 +0.86%. Lamb Weston jumped 12% on strong results; Arrivent plunged 58%.
globenewswire.com Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation…
globenewswire.com Spyre Therapeutics Announces Proposed Public Offering of its Common Stock WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation…
defenseworld.net Spyre (NASDAQ: SYRE) legal chief trims stake in planned share sale What happened Spyre Therapeutics, Inc. (NASDAQ: SYRE) Chief Legal Officer and Corporate Secretary Heidy King-Jones sold 28,933 shares on 2026-10-01. The Form 4 shows five sale blocks at…
globenewswire.com Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation…
defenseworld.net Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – Should You Buy? Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report)'s stock price gapped up prior to trading on Wednesday. The stock had previously closed at $84.72, but opened at $88.64. Spyre Therapeutics…- benzinga.com JP Morgan Initiates Coverage On Spyre Therapeutics with Overweight Rating, Announces Price Target of $110 JP Morgan analyst Hardik Parikh initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Overweight rating and announces Price Target of $110.
benzinga.com BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
benzinga.com Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
defenseworld.net Gain Therapeutics (NASDAQ:GANX) versus Spyre Therapeutics (NASDAQ:SYRE) Head to Head Comparison Spyre Therapeutics (NASDAQ: SYRE - Get Free Report) and Gain Therapeutics (NASDAQ: GANX - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
defenseworld.net California State Teachers Retirement System Buys 5,683,670 Shares of Spyre Therapeutics, Inc. $SYRE California State Teachers Retirement System grew its stake in shares of Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 9,594.0% in the undefined quarter, according to its most recent Form 13F filing with…
defenseworld.net 11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ: SYRE) during the second quarter, according to the company in its most recent 13F filing with the…
seekingalpha.com Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
zacks.com Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy.
benzinga.com Wedbush Reiterates Outperform on Spyre Therapeutics, Maintains $123 Price Target Wedbush analyst David Nierengarten reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and maintains $123 price target.- benzinga.com BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $121 price target.
- benzinga.com Spyre's SPY003 Met Its Primary Endpoint SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included…
globenewswire.com Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p
globenewswire.com Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation…
globenewswire.com Spyre Therapeutics to Participate in Upcoming September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the…
zacks.com Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? Spyre Therapeutics (SYRE) reported earnings 30 days ago. What's next for the stock?
benzinga.com Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127 Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.
zacks.com SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
benzinga.com Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.
benzinga.com Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles Spyre Therapeutics shared Phase 2 SKYWAY trial data for SPY072 in rheumatoid arthritis. The therapy missed internal priority benchmarks.
benzinga.com Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123 Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and lowers the price target from $130 to $123.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics…
benzinga.com Intuit, Zoom, Qfin Holdings And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session US stock futures mixed, Intuit shares dip 11.7% after reporting Q4 revenue of $4.35B and adjusted earnings of $4.03/share. FY27 guidance below estimates. Other stocks moving lower in pre-market…- benzinga.com BTIG Maintains Buy on Spyre Therapeutics, Lowers Price Target to $121 BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $132 to $121.
benzinga.com Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Alector (NASDAQ:ALEC) shares increased by 9.7% to $2.59 during Tuesday's after-market session. The company's market cap stands at $256.8 million. NeuroSense Therapeutics (NASDAQ:NRSN) shares…
globenewswire.com Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory…
benzinga.com Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downgrades on analyst ratings page.- benzinga.com BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132 BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $112 to $132.
benzinga.com Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007 To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT, a randomized Phase 2 proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F in…- benzinga.com Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115 Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $90 to $115.
- benzinga.com Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130 Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $115 to $130.
- benzinga.com Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130 Wedbush analyst David Nierengarten maintains Spyre Therapeutics (NASDAQ:SYRE) with a Outperform and raises the price target from $100 to $130.
- benzinga.com Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.73) by 50.68 percent. This is a 26.53 percent increase over losses of…
benzinga.com Goldman Sachs Posts Upbeat Q2 Earnings, Joins SK Hynix, Tower Semiconductor And Other Big Stocks Moving Higher On Tuesday Goldman Sachs (NYSE: GS) shares surged 6.9% after beating earnings estimates. Other big gainers include PHOE, SKHY, GALT, AXTI, FCEL, AAOI, CHRN, TSEM, YSS, RGC, and OKTA.
benzinga.com Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 falls 200 pts. Rivian (RIVN) drops after public offering announcement. Other stocks also down in pre-market.
benzinga.com FedEx, Cerebras Systems And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.